Exhibit 10.1
 
CLEVELAND BIOLABS, INC.
EMPLOYMENT AGREEMENT
 
THIS EMPLOYMENT AGREEMENT (the “Agreement”), made as of this 4th day of
August, 2011, is entered into by Cleveland Biolabs, Inc., a Delaware corporation
with its principal place of business at 73 High Street, Buffalo, NY 14203 (and
together with its subsidiaries, affiliates, successors or assigns the
“Company”), and C. Neil Lyons, (the “Executive”).
 
PRELIMINARY RECITALS
 
A.The Company, among other things, is engaged in the business of conducting
research and development of new pharmaceuticals in the field of cancer treatment
and that provide protection for cells against harmful radiation (the
“Business”).
 
B.Executive has been offered a position to serve as the Company’s Chief
Financial Officer.
 
C.The Company and Executive desire to formally state the terms of said
employment and set forth the terms and conditions of Executive’s employment with
the Company in this Agreement.
 
NOW, THEREFORE, in consideration of the premises, the mutual covenants of the
parties hereinafter set forth and other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the parties hereto
hereby agree as follows:
 
1.  Employment.
 
1.1  Engagement; Duties and Powers. The Company agrees to employ Executive, and
Executive agrees to accept employment with the Company, as Chief Financial
Officer for the Term and in accordance with the terms and conditions of this
Agreement. During the Term, Executive shall serve as the Company’s Chief
Financial Officer and shall have such responsibilities, duties and authorities,
and shall render such services of an executive and administrative character or
act in such other capacity for the Company and its affiliates, as the board of
directors of the Company (the “Board”) shall from time to time lawfully direct.
Executive shall perform the duties and carry out the responsibilities assigned
to him, to the best of his ability, in a trustworthy, businesslike and efficient
manner for the purpose of advancing the business of the Company. Executive
acknowledges that his duties and responsibilities hereunder will require his
full business time and best efforts and agrees that, during the Term, he will
not engage in any other business activity or have any business pursuits or
interests which materially interfere or conflict with the performance of his
duties hereunder, provided, that nothing in this Section 1.1 shall be deemed to
prohibit Executive from making Permitted Investments. Executive may accept
positions on grant panels, boards of Directors, and act as a consultant for
compensation with the permission of the Board.
 
1.2  Term. The engagement of Executive under this Agreement shall begin on
September 1, 2011 (“Start Date”) and shall continue through and until August 31,
2012 (the “Initial Period”) unless extended as provided in this Section 1.2.
Thereafter, the term of this Agreement shall automatically renew and extend for
additional consecutive one-year periods (“Renewal Periods”) unless one of the
parties shall deliver a written notice of termination to the other party at
least sixty (60) days prior to the expiration of the Initial Period or any
Renewal Period. The Initial Period through the then current Renewal Period, if
any, is hereinafter referred to as the “Term.” Notwithstanding anything to the
contrary contained herein, the Term is subject to termination pursuant to
Section 1.3.
 
 
 

--------------------------------------------------------------------------------

 
 
1.3  Termination.
 
(a)  If Executive dies during the Term, this Agreement shall automatically
terminate on the date of Executive’s death.
 
(b)  The Company may terminate Executive’s employment hereunder upon written
notice to Executive at any time (i) due to the Permanent Disability of Executive
or (ii) for Cause or without Cause, for any or no reason. Such termination shall
be effective upon the date of service of such notice pursuant to Section 14.6.
 
For purposes of this Agreement, “Cause” means the occurrence of any of the
following events, as determined in the reasonable good faith judgment of the
Board:
 
(i)  the failure of Executive to perform his duties hereunder or comply with
reasonable directions of the Board which continues for ten (10) days after the
Board has given written notice to Executive, specifying in reasonable detail the
manner in which Executive has failed to perform such duties or comply with such
directions;
 
(ii)  the determination by the Board in the exercise of its reasonable judgment
that Executive has committed an act or acts constituting (a) a felony,
(b) dishonesty or disloyalty with respect to the Company or (c) fraud;
 
(iii)  the determination by the Board in the exercise of its reasonable judgment
that Executive has committed an act, or has failed to take action, which act or
failure to take action adversely affects the Company’s business or reputation;
 
(iv)  the breach, non-performance or non-observance of any of the terms of this
Agreement (other than as described in clause (i) above) or any other agreement
to which Executive and the Company are parties, by Executive, if such breach,
non-performance or non-observance shall continue beyond a period of ten (10)
business days immediately after written notice thereof by the Company to
Executive; or
 
(v)  notwithstanding clause (iv) above, immediately upon any breach of the
Restrictive Covenants.
 
(c)  Executive may terminate and resign from his Employment hereunder upon not
less than sixty (60) days prior written notice to the Company.
 
Executive shall be deemed to have a “Permanent Disability” for purposes of this
Agreement if he suffers a physical or mental illness, injury or infirmity that
prevents him from performing, with or without reasonable accommodations, his
essential job functions under this Agreement, for a total period of 120 days in
any 360-day period. The Board shall determine, according to the facts then
available, whether and when the Permanent Disability of Executive has occurred.
Such determination shall not be arbitrary or unreasonable, and the Board may,
but shall not be required to, take into consideration the opinion of Executive’s
personal physician, if reasonably available, and such determination by the Board
shall be final and binding on the parties hereto.
 
2.  Compensation and Benefits.
 
2.1  Base Salary. As consideration for the services of Executive hereunder, the
Company shall pay Executive an annual base salary of $250,000 (the “Base
Salary”), payable in accordance with the Company’s customary payroll practices
as in effect from time to time. Notwithstanding the foregoing, during the period
beginning on and including January 1, 2012 and for each year during the Term
thereafter, the Board, in its sole discretion, may elect to cause the Company to
adjust the Executive’s Base Salary by an amount to be determined by the Board in
its sole judgment based upon Executive’s and the Company’s performance and the
achievement of the other goals and objectives approved by the Board for such
year.
 
 
2

--------------------------------------------------------------------------------

 
 
2.2  Stock Options.  Executive shall be granted an option to purchase 125,000
shares of the Company’s common stock (NASDAQ: CBLI).  The stock options will be
granted as of Executive’s Start Date and will have the following parameters:

(a)    The per-share price of the stock option will be the fair market value as
determined per the Cleveland BioLabs, Inc. Guidelines for Equity Awards;

(b)            The stock options will vest over three years, provided Executive
continues to be employed by the Company on each respective vesting date: 25%
upon the first day of employment, and an additional 25% on the employment
anniversary date for each of the next three years.

(c)            The stock option will be subject to the terms of the Company’s
2006 Equity Incentive Plan (as amended and restated effective April 29, 2008 and
as may be amended from time-to-time) and standard stock option agreement.

2.3  Bonus. Executive shall be eligible to participate in the bonus program
established by the Cleveland BioLabs Executive Compensation Program, subject to
the terms and conditions of that program, as revised from time to time.  For the
fiscal year ending December 31, 2011, Executive will be eligible to participate
in such bonus program on a prorated basis, and Executive’s bonus will be
measured against the Company’s achievement of (1) stock performance milestones,
(2) scientific milestones, (3) business milestones, (4) financial milestones,
and (5) corporate governance, each of which will be weighted by the Compensation
Committee.
 
2.4  Compensation After Termination.
 
(a)  If Executive is terminated by the Company for Cause or resigns, then the
Company shall have no further obligations hereunder or otherwise with respect to
Executive’s employment hereunder from and after the date of said termination
(except payment of the Base Salary and other amounts owed to Executive for
reimbursable business expenses accrued through the date of said termination),
and the Company shall continue to have all other rights available hereunder
(including, without limitation, all rights under the Restrictive Covenants at
law or in equity).
 
(b)  If Executive is terminated by the Company without Cause, Executive shall be
entitled to receive as severance pay an amount equal to the Base Salary that
would otherwise have been payable if Executive continued his employment
hereunder, for a six (6) month period, payable in accordance with the Company’s
payroll policies, reduced by the amount of compensation earned by Executive at
other employment, provided, Executive signs a general release agreement in a
form to be provided by the Company. The Company shall have no other obligations
hereunder or otherwise with respect to Executive’s employment from and after the
termination date, and the Company shall continue to have all other rights
available hereunder (including, without limitation, all rights under the
Restrictive Covenants at law or in equity).

(c)  If Executive is terminated due to Permanent Disability or death, Executive
or Executive’s estate, as the case may be, shall be entitled to receive as
severance pay an amount equal to the Base Salary that would otherwise have been
payable if Executive continued his employment hereunder for the period that
otherwise would be remaining in the Term (without any further adjustment as
described in Section 2.1), payable in accordance with the Company’s payroll
policies, provided, Executive or his estate signs a general release agreement in
a form to be provided by the Company. Notwithstanding the foregoing, in the
event Executive is Permanently Disabled or dies as a result of, or in the
conduct of, his employment activities hereunder, then Executive or Executive’s
estate, as the case may be, shall be entitled to receive severance pay in an
amount equal to the Base Salary that would otherwise have been payable if
Executive continued his employment hereunder (without any further adjustment as
described in Section 2.1) for a period of not less than eighteen (18) months,
payable in accordance with the Company’s payroll policies, provided, Executive
or his estate signs a general release agreement in a form to be provided by the
Company. The Company shall have no other obligations hereunder or otherwise with
respect to Executive’s employment from and after the termination date, and the
Company shall continue to have all other rights available hereunder (including,
without limitation, all rights under the Restrictive Covenants at law or in
equity).
 
 
3

--------------------------------------------------------------------------------

 
 
2.5  Profit Sharing, Pension and Salary Deferral Benefits. It is understood by
the parties to this Agreement that, during the Term, Executive shall be entitled
to participate in or accrue benefits under any pension, salary deferral or
profit sharing plan now existing or hereafter created for employees of the
Company upon terms and conditions equivalent to those which the Company may
provide for other key management employees.
 
2.6  Fringe Benefits and Expenses During the Term.
 
(a)  Executive shall be eligible to participate in any benefit plans maintained
by the Company for its key management employees from time to time, including,
without limitation, group life, disability and medical insurance in accordance
with such plans as from time to time in effect and applicable to key management
employees of the Company.
 
(b)  Executive shall be entitled to three (3) weeks paid vacation per year for
the first year, and four (4) weeks paid vacation per year thereafter, earned pro
rata during his employment, to be taken at such times as may be approved by the
Board or its authorized designees. The maximum vacation pay that may accrue is
four (4) weeks (“Vacation Cap”). When Executive accrues four (4) weeks of
vacation, no further vacation will accrue until he uses vacation time and
reduces the accrued vacation time below the vacation cap. He will then accrue
vacation time until the vacation cap of four weeks is reached.
 
(c)  The Company shall provide Executive sick days on substantially the same
terms as offered to other key management employees.
 
(d)  The Company shall reimburse Executive for all ordinary, necessary and
reasonable travel and other business expenses incurred by him in connection with
the performance of his duties hereunder, in accordance with the Company’s
policy. Such reimbursement shall be made upon presentation of itemized expense
statements and such other supporting documentation as the Company may reasonably
require.
 
2.6  Taxes, Etc. All compensation payable to Executive hereunder is stated in
gross amount and shall be subject to all applicable withholding taxes, other
normal payroll and any other amounts required by law to be withheld.
 
3.  Confidentiality.
 
3.1  Company Information. Executive agrees at all times during the term of his
employment and thereafter, to hold in strictest confidence, and not to use,
except for the benefit of the Company, or to disclose to any person, firm or
corporation without written authorization of the Board of Directors of the
Company, any Confidential Information of the Company, except under a
non-disclosure agreement duly authorized and executed by the Company. Executive
understands that “Confidential Information” means any non-public information
that relates to the actual or anticipated business or research and development
of the Company, technical data, trade secrets or know-how, including, but not
limited to, research, product plans or other information regarding Company’s
products or services and markets therefor, customer lists and customers
software, developments, inventions, processes, formulas, technology, designs,
drawings, engineering, hardware configuration information, marketing, finances
or other business information. Executive further understands that Confidential
Information does not include any of the foregoing items which have become
publicly known and made generally available through no wrongful act of mine or
of others who were under confidentiality obligations as to the item or items
involved or improvements or new versions thereof.
 
 
4

--------------------------------------------------------------------------------

 
 
3.2  Former Employer Information. Executive agrees that he will not, during his
employment with the Company, improperly use or disclose any proprietary
information or trade secrets of any former or concurrent employer or other
person or entity and that Executive will not bring onto the premises of the
Company any unpublished document or proprietary information belonging to any
such employer, person or entity unless consented to in writing by such employer,
person or entity.
 
3.3  Third Party Information. Executive recognizes that the Company has received
and in the future will receive from third parties their confidential or
proprietary information subject to a duty on the Company’s part to maintain the
confidentiality of such information and to use it only for certain limited
purposes. Executive agrees to hold all such confidential or proprietary
information in the strictest confidence and not to disclose it to any person,
firm or corporation or to use it except as necessary in carrying out my work for
the Company consistent with the Company’s agreement with such third party.

4.  Inventions.
 
4.1  Inventions Retained and Licensed. Executive has attached hereto, as
Exhibit A, a list describing all inventions, original works of authorship,
developments, improvements, and trade secrets which were made prior to his
employment with the Company (collectively referred to as “Prior Inventions”),
which belong to Executive, which relate to the Company’s proposed business,
products or research and development, and which are not assigned to the Company
hereunder; or, if no such list is attached, Executive represents that there are
no such Prior Inventions. If in the course of Executive’s employment with the
Company, Executive incorporates into a Company product, process or service a
Prior Invention owned by Executive or in which Executive has an interest,
Executive hereby grants to the Company a nonexclusive, royalty-free, fully
paid-up, irrevocable, perpetual, worldwide license to make, have made, modified
use and sell such Prior Invention as part of or in connection with such product,
process or service, and to practice any method related thereto.
 
4.2  Assignment of Inventions. Executive agrees that he will promptly make full
written disclosure to the Company, will hold in trust for the sole right and
benefit of the Company, and hereby assign to the Company, or its designee, all
my right, title, and interest in and to any and all inventions, original works
of authorship, developments, concepts, improvements, designs, discoveries,
ideas, trademarks or trade secrets, whether or not patentable or registrable
under copyright or similar laws, which Executive may solely or jointly conceive
or develop or reduce to practice, or cause to be conceived or developed or
reduced to practice, during the period of time Executive am in the employ of the
Company (collectively referred to as “Inventions”). Executive further
acknowledges that all original works of authorship which are made by me (solely
or jointly with others) within the scope of and during the period of my
employment with the Company and which are protectible by copyright are “works
made for hire,” as that term is defined in the United States Copyright Act.
Executive understands and agrees that the decision whether or not to
commercialize or market any invention developed by me solely or jointly with
others is within the Company’s sole discretion and for the Company’s sole
benefit and that no royalty will be due to him as a result of the Company’s
efforts to commercialize or market any such invention.
 
4.3  Inventions Assigned to the United States. Executive agrees to assign to the
United States government all his right, title, and interest in and to any and
all Inventions whenever such full title is required to be in the United States
by a contract between the Company and the United States or any of its agencies.
 
4.4  Maintenance of Records. Executive agrees to keep and maintain adequate and
current written records of all Inventions made by him (solely or jointly with
others) during the term of his employment with the Company. The records will be
in the form of notes, sketches, drawings, and any other format that may be
specified by the Company. The records will be available to and remain the sole
property of the Company at all times.
 
4.5  Patent and Copy Registrations. Executive agrees to assist the Company, or
its designee, at the Company’s expense, in every proper way to secure the
Company’s rights in the Inventions and any copyrights, patents, mask work rights
or other intellectual property rights relating thereto in any and all countries,
including the disclosure to the Company of all pertinent information and data
with respect thereto, the execution of all applications, specifications, oaths,
assignments and all other instruments which the Company shall deem necessary in
order to apply for and obtain such rights and in order to assign and convey to
the Company, its successors, assigns, and nominees the sole and exclusive
rights, title and interest in and to such Inventions, and any copyrights,
patents, mask work rights or other intellectual property rights relating
thereto. Executive further agree that my obligation to execute or cause to be
executed, when it is in my power to do so, any such instrument or papers shall
continue after the termination of this Agreement. If the Company is unable
because of my mental or physical incapacity or for any other reason to secure my
signature to apply for or to pursue any application for any United States or
foreign patents or copyright registrations covering Inventions or original works
of authorship assigned to the Company as above, then Executive hereby
irrevocably designates and appoints the Company and its duly authorized officers
and agents as his agent and attorney in fact, to act for and in his behalf and
stead to execute and file any such applications and to do all other lawfully
permitted acts to further the prosecution and issuance of letters patent or
copyright registrations thereon with the same legal force and effect as if
executed by him.
 
 
5

--------------------------------------------------------------------------------

 
 
5.  Conflicting Employment. Executive agrees that, during the term of his
employment with the Company, Executive will not engage in any other employment,
occupation or consulting directly related to the business in which the Company
is now involved or becomes involved during the term of his employment, nor will
Executive engage in any other activities that conflict with his obligations to
the Company, unless written consent is given by the Board of Directors of the
Company.
 
6.  Returning Company Documents. Executive agrees that, at the time of leaving
the employ of the Company or at any time the Company requests, he will deliver
to the Company (and will not keep in his possession, recreate or deliver to
anyone else) any and all devices, records, data, notes, reports, proposals,
lists, correspondence, specifications, drawings blueprints, sketches, materials,
equipment, other documents or property, or reproductions of any aforementioned
items developed by Executive pursuant to his employment with the Company or
otherwise belonging to the Company, its successors or assigns, including,
without limitation, those records maintained pursuant to Section 4.4. In the
event of the termination of Executive’s employment, Executive agrees to sign and
deliver the “Termination Certification” attached hereto as Exhibit B.
 
7.  Notification of New Employer. In the event that Executive leaves the employ
of the Company, Executive hereby grants consent to notification by the Company
to his new employer about his rights and obligations under this Agreement.
 
8.  Solicitation of Employees. Executive agrees that for a period of twelve (12)
months immediately following the termination of his relationship with the
Company for any reason, whether with or without cause, Executive shall not
either directly or indirectly solicit, induce, recruit or encourage any of the
Company’s employees to leave their employment, or take away such employees, or
attempt to solicit, induce, recruit, encourage or take away employees of the
Company, either for himself or for any other person or entity.  This restriction
shall apply only to those employees of the Company with whom Executive came into
contact or about whom Executive learned Confidential Information during the last
two (2) years of his employment with the Company.
 
9.  Non-Competition. Executive agrees that during the period of employment and
for a period of two (2) years immediately following the termination of his
relationship with the Company for any reason, whether with or without cause,
Executive shall not directly or indirectly own, manage, operate, consult or to
be employed in a business substantially similar to (as defined by the Company’s
therapeutic area and core technology), or competitive with, the Business of the
Company and its successors and assigns or such other business activity in which
the Company and its successors and assigns may substantially engage during the
Term.  In recognition of the national nature of the Company’s Business, which
includes the sale of its products and services nationwide, this restriction
shall apply throughout the United States.

10.  Conflict of Interest Guidelines. Executive agrees to diligently adhere to
the Conflict of Interest Guidelines attached as Exhibit D hereto.
 
 
6

--------------------------------------------------------------------------------

 
 
11.  Representations. Executive agrees to execute any proper oath or verify any
proper document required to carry out the terms of this Agreement. Executive
represent that his performance of all the terms of this Agreement will not
breach any agreement to keep in confidence proprietary information acquired by
Executive in confidence or in trust prior to Executive’s employment by the
Company. Executive hereby represent and warrant that Executive have not entered
into, and Executive will not enter into, any oral or written agreement in
conflict herewith.
 
12.  Policy Manual. Executive agrees that he is responsible for knowing the
contents of the Company’s Policy Manual, the contents of which may be modified
or eliminated at any time.
 
13.  Enforcement . Executive acknowledges and agrees that compliance with the
covenants set forth in this Agreement is necessary to protect the Confidential
Information and Trade Secrets, business and goodwill of the Company, and that
any breach of this Agreement will result in irreparable and continuing harm to
the Company, for which money damages may not provide adequate
relief.  Accordingly, in the event of any breach or anticipatory breach of this
Agreement by Executive, or Executive’s claim in a declaratory judgment action
that all or part of this Agreement is unenforceable, the parties agree that the
Company shall be entitled to the following particular forms of relief as a
result of such breach, in addition to any remedies otherwise available to it at
law or equity:  (a) injunctions, both preliminary and permanent, enjoining or
restraining such breach or anticipatory breach, and Executive hereby consents to
the issuance thereof forthwith and without bond by any court of competent
jurisdiction; and (b) recovery of all reasonable sums and costs, including
attorneys’ fees, incurred by the Company to defend or enforce the provisions of
this Agreement.

14.  Governing Law and Choice of Forum. This Agreement shall be governed by, and
construed in accordance with, the laws of the State of New York, without regard
to its conflict of laws provisions.  The parties being desirous of having any
disputes resolved in a forum having a substantial body of law and experience
with the matters contained herein, the parties agree that any action or
proceeding with respect to this Agreement and Executive’s employment shall be
brought exclusively in the Supreme Court of the State of New York, Erie County,
or in the United States District Court for the Western District of New York, or
in any other court of competent jurisdiction sitting in the State of New York,
Erie County, and the parties agree to the personal jurisdiction thereof.  The
parties hereby irrevocably waive any objection they may now or hereafter have to
the laying of venue of any such action in the said court(s), and further
irrevocably waive any claim they may now or hereafter have that any such action
brought in said court(s) has been brought in an inconvenient forum.  The parties
recognize that, should any dispute or controversy arising from or relating to
this agreement be submitted for adjudication to any court, arbitration panel or
other third party, the preservation of the secrecy of Confidential Information
or Trade Secrets may be jeopardized.  Consequently, the parties agree that all
issues of fact shall be tried without a jury.
 
14.  Miscellaneous.
 
14.1  Income Tax Treatment. Executive and the Company acknowledge that it is the
intention of the Company to deduct all amounts paid under Section 2 hereof as
ordinary and necessary business expenses for income tax purposes. Executive
agrees and represents that he will treat all amounts paid hereunder as ordinary
income (except for expense reimbursement) for income tax purposes.
 
14.2  Assignment.  This Agreement shall be binding upon Executive, Executive’s
heirs, executors and administrators, and upon the Company, and its successors
and assigns, and shall inure to the benefit of the Company, and its successors
and assigns.  This Agreement may not be assigned by Executive.  This Agreement
may be enforced by the Company’s successors and assigns.
 
14.3  Severability.  The Parties agree they have attempted to limit the scope of
the post-employment restrictions contained herein to the extent necessary to
protect the Company’s Confidential Information and Trade Secrets, client
relationships and good will.  It is the desire and intent of the parties that
the provisions of this Agreement shall be enforced to the fullest extent
permissible under applicable laws and public policies.  Employee agrees that the
provisions of this Agreement shall be enforced to the fullest extent permissible
under applicable laws and public policies.  Accordingly, if any term or
provision of this Agreement or any portion thereof is declared illegal or
unenforceable by any court of competent jurisdiction, such provision or portion
thereof shall be deemed modified so as to render it enforceable, and to the
extent such provision or portion thereof cannot be rendered enforceable, this
Agreement shall be considered divisible as to such provision which shall become
null and void, leaving the remainder of this Agreement in full force and effect.
 
 
7

--------------------------------------------------------------------------------

 
 
14.4  Counterparts. This Agreement may be executed in multiple counterparts,
each of which shall be deemed an original, but all of which taken together shall
constitute one and the same Agreement.
 
14.5  Descriptive Headings; Interpretation. The descriptive headings in this
Agreement are inserted for convenience of reference only and are not intended to
be part of or to affect the meaning or interpretation of this Agreement. The use
of the word “including” in this Agreement shall be by way of example rather than
by limitation.

14.6  Notices. All notices, demands or other communications to be given or
delivered under or by reason of the provisions of this Agreement shall be in
writing and shall be deemed to have been duly given if (i) delivered personally
to the recipient, (ii) sent to the recipient by reputable express courier
service (charges prepaid) or mailed to the recipient by certified or registered
mail, return receipt requested and postage prepaid, or (iii) transmitted by
telecopy to the recipient with a confirmation copy to follow the next day to be
delivered by overnight carrier. Such notices, demands and other communications
shall be sent to the addresses indicated below:
  

 
To the Company:
Cleveland BioLabs, Inc.
   
73 High Street
   
Buffalo, NY 14203
   
Attention: Chief Executive Officer
   
Facsimile: (716) 849-6820

 

 
with a copy to:
                         

 

 
To Executive:
C. Neil Lyons
   
7805 Brown Bridge
Road                                                                
   
Highland, Maryland  20777     
   
Facsimile:
   
with a copy to:

 

 
with a copy to: 
__________________________
   
__________________________
   
__________________________
   
Attention:__________________
   
Facsimile: __________________

 
or to such other address or to the attention of such other person as the
recipient party shall have specified by prior written notice to the sending
party. Date of service of such notice shall be (w) the date such notice is
personally delivered, (x) three days after the date of mailing if sent by
certified or registered mail, (y) one day after the date of delivery to the
overnight courier if sent by overnight courier or (z) the next business day
after the date of transmittal by telecopy.
 
 
8

--------------------------------------------------------------------------------

 
 
14.7  Preamble; Preliminary Recitals. The Preliminary Recitals set forth in the
Preamble hereto are hereby incorporated and made part of this Agreement.
 
14.8  Entire Agreement. Except as otherwise expressly set forth herein, this
Agreement sets forth the entire understanding of the parties, and supersedes and
preempts all prior oral or written understandings and agreements with respect to
the subject matter hereof.
 
14.9  No Strict Construction. The language used in this Agreement will be deemed
to be the language chosen by the parties hereto to express their mutual intent,
and no rule of strict construction will be applied against any party hereto.
 
14.10  Amendment and Waivers.  The failure of either the Company or Executive,
whether purposeful or otherwise, to exercise in any instance any right, power,
or privilege under this Agreement or under law shall not constitute a waiver of
the same or any other right, power, or privilege in any other instance.  Any
waiver by the Company or by Executive must be in writing and signed by either
Executive, if Executive is seeking to waive any of his rights under this
Agreement, or by the President of the Company, if the Company is seeking to
waive any of its rights under this Agreement.  No modification of this Agreement
shall be valid unless made in a writing signed by both parties hereto, wherein
specific reference is made to this Agreement.

14.11  Section 409 A.

(a) This Agreement is intended to comply with Section 409A of the Internal
Revenue Code of 1986, as amended ("Section 409A") and shall, to the extent
practicable, be construed in accordance therewith. Accordingly, notwithstanding
anything in this Agreement to the contrary, if the Company determines that
Executive is a "specified employee" (as defined in Code Section
409A(a)(2)(B)(i)) at the time of his or her Separation from Service (as defined
under Section 409A) and any amount payable to Executive under this Agreement is
a deferral of compensation subject to the additional tax described in Code
Section 409A(a)(1)(B) and would be considered a payment upon Executive’s
Separation from Service, then notwithstanding anything in this Agreement to the
contrary, such amount shall not be paid before the date that is the earlier of
(i) six (6) months and one (1) day after Executive’s Separation from Service or
(ii) Executive’s death (the "Delay Period"). Upon the expiration of the Delay
Period, the initial payment following the Delay Period shall include a lump sum
payment equal to those payments that otherwise would have been paid if the delay
had not applied, and any remaining payments due shall be payable in accordance
with their original payment schedule.
 
(b) If either party to this Agreement reasonably determines that any amount
payable pursuant to this Agreement would result in adverse tax consequences
under Section 409A (including, but not limited to, the additional tax described
in Code Section 409A(a)(1)(B)), then such party shall deliver written notice of
such determination to the other party, and the parties hereby agree to work in
good faith to amend this Agreement so it (i) is exempt from, or compliant with,
the requirements of Section 409A and (ii) preserves as nearly as possible the
original intent and economic effect of the affected provisions.
 

     
Date: August 4, 2011
 
Signature
           
By:  
   
/s/ C. Neil Lyons
C. Neil Lyons
               
CLEVELAND BIOLABS, INC.
                   
By:  
/s/ Yakov Kogan
Yakov Kogan, Ph.D.
   
Its:
Chief Operating Officer

 
 
9

--------------------------------------------------------------------------------

 
 
Exhibit A
 
LIST OF PRIOR INVENTIONS
AND ORIGINAL WORKS OF AUTHORSHIP
 
Title
 
Date
 
Identifying Number
or Brief Description
                   

 
x No inventions or improvements
 
___  Additional Sheets Attached
 
Signature of Executive: ________________________________    
 
Print Name of Executive: _______________________________    
 
Date: _____________________________________________      
 
 
10

--------------------------------------------------------------------------------

 

Exhibit B
 
CLEVELAND BIOLABS, INC.
TERMINATION CERTIFICATION
 
This is to certify that the undersigned does not have in my possession, nor have
I failed to return, any devices, records, data, notes, reports, proposals,
lists, correspondence, specifications, drawings, blueprints, sketches,
materials, equipment, other documents or property, or reproductions of any
aforementioned items belonging to Cleveland BioLabs, Inc., its subsidiaries,
affiliates, successors or assigns (together, the “Company”).
 
I further certify that I have complied with all the terms of the Company’s
Employment Agreement signed by me, including the reporting of any inventions and
original works of authorship (as defined therein), conceived or made by me
(solely or jointly with others) covered by that agreement.
 
I further agree that, in compliance with the Employment Agreement, I will
preserve as confidential all trade secrets, confidential knowledge, data or
other proprietary information relating to products, processes, know-how,
designs, formulas, developmental or experimental work, computer programs, data
bases, other original works of authorship, customer lists, business plans,
financial information or other subject matter pertaining to any business of the
Company or any of its employees, clients, consultants or licensees.
 
I further agree that for twelve (12) months from this date, I will not solicit,
induce, recruit or encourage any of the Company’s employees to leave their
employment.
 
I further agree that for two (2) years from this date I will not directly or
indirectly own, manage, operate, consult or to be employed in a business
substantially similar to, or competitive with, the present business of the
Company and its successors and assigns or such other business activity in which
the Company and its successors and assigns may substantially engage during the
term of employment
 
Date: ___________________
     
(Employee’s Signature) __________________________
             
  
(Type/Print Employee’s Name)
       

 
 
11

--------------------------------------------------------------------------------

 
 
Exhibit C
 
CLEVELAND BIOLABS, INC.
CONFLICT OF INTEREST GUIDELINES
 
It is the policy of Cleveland BioLabs, Inc. to conduct its affairs in strict
compliance with the letter and spirit of the law and to adhere to the highest
principles of business ethics. Accordingly, all officers, employees and
independent contractors must avoid activities which are in conflict, or give the
appearance of being in conflict, with these principles and with the interests of
the Company. The following are potentially compromising situations which must be
avoided. Any exceptions must be reported to the President and written approval
for continuation must be obtained.

1.Revealing confidential information to outsiders or misusing confidential
information. Unauthorized divulging of information is a violation of this policy
whether or not for personal gain and whether or not harm to the Company is
intended. (The Employment Agreement elaborates on this principle and is a
binding agreement.)
 
2.Accepting or offering substantial gifts, excessive entertainment, favors or
payments which may be deemed to constitute undue influence or otherwise be
improper or embarrassing to the Company.
 
3.Participating in civic or professional organizations that might involve
divulging confidential information of the Company.
 
4.Initiating or approving personnel actions affecting reward or punishment of
employees or applicants where there is a family relationship or is or appears to
be a personal or social involvement.
 
5.Initiating or approving any form of personal or social harassment of
employees.
 
6. Investing or holding outside directorship in suppliers, customers, or
competing companies, including financial speculations, where such investment or
directorship might influence in any manner a decision or course of action of the
Company.
 
7.Borrowing from or lending to employees customers or suppliers.
 
8.Acquiring real estate of interest to the Company.
 
9.Improperly using or disclosing to the Company any proprietary information or
trade secrets of any former or concurrent employer or other person or entity
with whom obligations of confidentiality exist.
 
10.Unlawfully discussing prices, costs, customers, sales or markets with
competing companies or their employees.
 
11.Making any unlawful agreement with distributors with respect to prices.
 
12.Improperly using or authorizing the use of any inventions which are the
subject of patent claims of any other person or entity.
 
13.Engaging in any conduct which is not in the best interest of the Company.
 
Each officer, employee and independent contractor must take every necessary
action to ensure compliance with these guidelines and to bring problem areas to
the attention of higher management for review. Violations of this conflict of
interest policy may result in discharge without warning.